Ochre Bio Strengthens Leadership with Former Eli Lilly and AstraZeneca Executive as RNA Therapeutics Company Expands
Oxford-based Ochre Bio has appointed Dr. Elaine Sullivan, former VP at Eli Lilly and AstraZeneca, as Senior Independent Non-Executive Director to support the company's RNA therapeutics development for chronic liver disease.
Boehringer Ingelheim Reports Promising Results for SIRP Inhibitors in Cancer Immunotherapy Trials
Boehringer Ingelheim's SIRP inhibitor BI 765063, when combined with PD-1 inhibitor ezabenlimab and cetuximab, showed manageable safety and promising antitumor activity in patients with recurrent/metastatic head and neck cancer.
BioMed X and Boehringer Ingelheim Complete Groundbreaking Schizophrenia Research Project
BioMed X Institute and Boehringer Ingelheim have successfully completed their second neuroscience collaboration focused on schizophrenia, with Boehringer Ingelheim acquiring the research data for further development.
Dual mTORC1/2 Inhibitor BI 860585 Shows Promise in Phase I Breast Cancer Trial
A Phase I study of BI 860585, a novel dual mTORC1/2 inhibitor, demonstrated manageable safety profile and preliminary efficacy in advanced breast cancer patients.
BioMed X and Boehringer Ingelheim Launch Initiative to Revolutionize Retinal Drug Delivery
BioMed X and Boehringer Ingelheim have announced a global call for proposals to develop next-generation intraocular biologics, marking their second research initiative at the XSeed Labs incubator in Ridgefield, Connecticut.
Brainomix's e-Lung AI Technology Validated for Progressive Pulmonary Fibrosis Detection in Boehringer Ingelheim Collaboration
New studies presented at the American Thoracic Society Conference validate Brainomix's FDA-cleared e-Lung technology as a reliable tool for identifying progressive pulmonary fibrosis with greater sensitivity than conventional methods.
Appeals Court Rejects AstraZeneca's Challenge to Medicare Drug Price Negotiation Program
The 3rd U.S. Circuit Court of Appeals dismissed AstraZeneca's lawsuit against Medicare's drug price negotiation program, ruling the company failed to demonstrate specific injury or due process violations.
NPPA Sets Retail Prices for 84 Drugs Including Empagliflozin Combinations Following Patent Expiry
India's National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 84 new drug formulations, including 36 combinations containing the recently off-patent diabetes medication empagliflozin.
Pharma Leadership Shuffle: Key Executive Moves in Early 2025 Reshape Industry Landscape
The pharmaceutical industry has experienced significant leadership changes in early 2025, with major transitions at companies including Pfizer, Boehringer Ingelheim, and Takeda.
ViVerita Therapeutics Partners with Boehringer Ingelheim to Discover Novel Cancer Targets Using In Vivo CRISPR Platform
ViVerita Therapeutics announced a strategic research collaboration with Boehringer Ingelheim to accelerate discovery and validation of novel therapeutic targets for cancer treatment.